Mitotic rate in melanoma: Prognostic value of immunostaining and computer-assisted image analysis

American Journal of Surgical Pathology

Volumn 37, Issue 6, 2013, Pages 882-889

  Hale, Christopher S ^a   Qian, Meng ^a   Ma, Michelle W ^b,c   Scanlon, Patrick ^b,c   Berman, Russell S ^a,b,c   Shapiro, Richard L ^a,b,c   Pavlick, Anna C ^a,b,c   Shao, Yongzhao ^a,b,c   Polsky, David ^a,b,c   Osman, Iman ^b,c   Darvishian, Farbod ^a,b,c  

^a Interdisciplinary Melanoma Cooperative Group   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Computer assisted image analysis; Digital pathology; Melanoma; MPM 2; PHH3; Prognosis; Recurrence

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MELANOMA; METHODOLOGY; MIDDLE AGED; MITOSIS INDEX; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MITOTIC INDEX; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880165136     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31827e50fa     Document Type: Article

References (36)

1. Badalamenti G, Rodolico V, Fulfaro F, et al. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol. 2007;18(suppl 6):36-40.
2. Baak JP, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol. 2005;23:5993-6001.
3. Layfield LJ, Liu K, Dodge R, et al. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology. Arch Pathol Lab Med. 2000;124:221-227.
4. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
5. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199-2205.
6. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
7. Barnhill RL, Katzen J, Spatz A, et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268-273.
8. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426-433.
9. Clark WH Jr, Elder DE, Dt Guerry, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
10. Lende TH, Janssen EA, Gudlaugsson E, et al. In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol. 2011;29:852-858.
11. Thunnissen FB, Ambergen AW, Koss M, et al. Mitotic counting in surgical pathology: sampling bias, heterogeneity and statistical uncertainty. Histopathology. 2001;39:1-8.
12. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol. 2007;127:380-384.
13. Ramsay JA, From L, Iscoe NA, et al. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol. 1995;105:22-26.
14. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056.
15. Hazan C, Melzer K, Panageas KS, et al. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer. 2002;95:634-640.
16. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30:83-89.
17. Escargueil AE, Larsen AK. Mitosis-specific MPM-2 phosphoryla-tion of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A. Biochem J. 2007;403:235-242.
18. Escargueil AE, Plisov SY, Filhol O, et al. Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469. J Biol Chem. 2000;275: 34710-34718.
19. Goto H, Tomono Y, Ajiro K, et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem. 1999;274:25543-25549.
20. Schimming TT, Grabellus F, Roner M, et al. pHH3 Immunostain-ing improves interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol. 2012;34:266-269.
21. Wich LG, Hamilton HK, Shapiro RL, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res. 2009;1:35-43.
22. Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res. 2012;22:1-8.
23. Cascinelli N, Ferrario M, Tonelli T, et al. A possible new tool for clinical diagnosis of melanoma: the computer. J Am Acad Dermatol. 1987;16(pt 1):361-367.
24. Soenksen D. Advances in digital pathology drive continued momentum and globalization. MLO Med Lab Obs. 2009;41:31.
25. Bossard C, Jarry A, Colombeix C, et al. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol. 2006;59:706-710.
26. Malon C, Brachtel E, Cosatto E, et al. Mitotic figure recognition: Agreement among pathologists and computerized detector. Anal Cell Pathol (Amst). 2012;35:97-100.
27. Angi M, Damato B, Kalirai H, et al. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol. 2011;89:e155-e160.
28. Casper DJ, Ross KI, Messina JL, et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol. 2010;32:650-654.
29. Ladstein RG, Bachmann IM, Straume O, et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.
30. Glatz K, Hartmann C, Antic M, et al. Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis. Am J Dermatopathol. 2010;32:643-649.
31. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117-122.
32. Orchard GE, Calonje E. The effect of melanin bleaching on immunohistochemical staining in heavily pigmented melanocytic neoplasms. Am J Dermatopathol. 1998;20:357-361.
33. Ikenberg K, Pfaltz M, Rakozy C, et al. Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma. J Cutan Pathol. 2012;39:324-330.
34. Ladstein RG, Bachmann IM, Straume O, et al. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol. 2012;132:1247-1252.
35. Roach BA, Burton AL, Mays MP, et al. Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg. 2010;200:759-763; discussion 63-64.
36. Davis FM, Tsao TY, Fowler SK, et al. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA. 1983;80:2926-2930.